

Serial No. 09/727,117

Atty. Docket No. Mo 6049

REMARKS

Applicants respectfully request reconsideration and reexamination of the present application in light of the amendments and the remarks below.

Claims 9-20 are pending in this application. Claims 1, 2, 6, 7, and 8 have been cancelled. Claims 3, 4, and 5 were cancelled in the Response mailed March 24, 2004.

New claims 11-20 have been added. Support for these new claims may be found, for example, on pages 10-13 of the specification.

Claims 9 and 10 have been amended. These claim amendments are made to clarify the subject matter therein. Therefore, these amendments are submitted in order to place the claims in condition for allowance, and do not disclaim any subject matter to which the Applicants are entitled.

Rejection Under 35 U.S.C. § 103(a)

The Examiner rejected claims 1, 2, and 6-10 under 35 U.S.C. § 103(a) as unpatentable over Dorn, et al., (U.S. Patent No. 6,232,328). Applicants respectfully traverse.

Claims 1, 2, 6, 7, and 8 have been cancelled, thereby obviating the rejection. Claims 9 and 10 have been amended. As amended, claims 9 and 10 recite processes for treating a mammal or premise infected with acarids by administering a composition comprising a pyrethroid and a chloronicotinyl compound.

As discussed in previous responses, Dorn, et al., do not teach or suggest the combination of a pyrethroid and a chloronicotinyl compound for treating a mammal or premise infected with acarids (e.g., ticks and mites).

It is therefore respectfully submitted that Dorn, et al., fail to teach or suggest the processes as presently claimed, and that the current invention is novel and nonobvious in view of the prior art references. For the foregoing reasons, Applicants respectfully request reconsideration and withdrawal of the present rejection.

CONCLUSION

For the foregoing reasons, Applicants submit that the claims are in condition for allowance and Applicants respectfully request reexamination of the present application, reconsideration and withdrawal of the present rejections, and entry of the amendments. Should there be any further matter requiring consideration, Examiner Qazi is invited to contact the undersigned counsel.

If there are any further fees due in connection with the filing of the present reply, please charge the fees to undersigned's Deposit Account No. 13-3372. If a fee is required for an extension of time not

Serial No. 09/727,117


Atty. Docket No. Mo 6049

accounted for, such an extension is requested and the fee should also be charged to undersigned's deposit account.

Respectfully submitted,

Date: December 22, 2004

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516-4175
Telephone: (203) 812-6450
Facsimile: (203) 812-6459



Susan M. Pellegrino
Reg. No. 48,972